EP4126945A4 - Méthodes et traitement impliquant un excès de light libre - Google Patents

Méthodes et traitement impliquant un excès de light libre Download PDF

Info

Publication number
EP4126945A4
EP4126945A4 EP21779221.7A EP21779221A EP4126945A4 EP 4126945 A4 EP4126945 A4 EP 4126945A4 EP 21779221 A EP21779221 A EP 21779221A EP 4126945 A4 EP4126945 A4 EP 4126945A4
Authority
EP
European Patent Office
Prior art keywords
methods
free light
treatment involving
excess free
involving excess
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21779221.7A
Other languages
German (de)
English (en)
Other versions
EP4126945A2 (fr
Inventor
Garry A. NEIL
Inbal ZAFIR-LAVIE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avalo Therapeutics Inc
Original Assignee
Avalo Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avalo Therapeutics Inc filed Critical Avalo Therapeutics Inc
Publication of EP4126945A2 publication Critical patent/EP4126945A2/fr
Publication of EP4126945A4 publication Critical patent/EP4126945A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
EP21779221.7A 2020-04-01 2021-03-31 Méthodes et traitement impliquant un excès de light libre Pending EP4126945A4 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063003826P 2020-04-01 2020-04-01
US202063027127P 2020-05-19 2020-05-19
US202163133636P 2021-01-04 2021-01-04
PCT/US2021/025068 WO2021202649A2 (fr) 2020-04-01 2021-03-31 Méthodes et traitement impliquant un excès de light libre

Publications (2)

Publication Number Publication Date
EP4126945A2 EP4126945A2 (fr) 2023-02-08
EP4126945A4 true EP4126945A4 (fr) 2024-02-28

Family

ID=77929895

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21779221.7A Pending EP4126945A4 (fr) 2020-04-01 2021-03-31 Méthodes et traitement impliquant un excès de light libre

Country Status (11)

Country Link
US (2) US11708406B2 (fr)
EP (1) EP4126945A4 (fr)
JP (1) JP2023520216A (fr)
KR (1) KR20220161387A (fr)
CN (1) CN115768791B (fr)
AU (1) AU2021248833A1 (fr)
BR (1) BR112022019112A2 (fr)
CA (1) CA3173873A1 (fr)
MX (1) MX2022011811A (fr)
TW (1) TW202204405A (fr)
WO (1) WO2021202649A2 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008027338A2 (fr) * 2006-08-28 2008-03-06 Kyowa Hakko Kirin Co., Limited Anticorps monoclonaux humains anti-hlight humain
US20190315876A1 (en) * 2018-01-24 2019-10-17 Capella Bioscience Ltd. Antigen Binding Molecules That Bind LIGHT

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6998108B1 (en) 1997-07-07 2006-02-14 La Jolla Institute For Allergy And Immunology Antibodies to p30 polypeptides and methods making and using same
US7118742B2 (en) 1997-07-07 2006-10-10 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US6140467A (en) 1997-07-07 2000-10-31 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
EP1274840B1 (fr) 2000-04-12 2007-06-20 La Jolla Institute For Allergy And Immunology Ligand pour mediateur d'entree du virus herpes simplex et procedes de mise en oeuvre
US8153123B2 (en) 2004-12-09 2012-04-10 La Jolla Institute For Allergy And Immunology Method for restoring dendritic cell populations
WO2010006071A1 (fr) 2008-07-08 2010-01-14 La Jolla Institute For Allergy And Immunology Complexes hvem/btla, hvem/cd160 et hvem/gd cis et leurs procédés d'utilisation
US8349320B2 (en) 2004-12-09 2013-01-08 La Jolla Institute For Allergy And Immunology Compositions and methods for modulating responses mediated or associated with BTLA activity
SI2292663T1 (sl) * 2006-08-28 2014-02-28 Kyowa Hakko Kirin Co., Ltd Antagonistična humana monoklonska protitelesa, specifična za humani LIGHT
EP2650018A3 (fr) 2007-05-14 2014-09-03 The University of Chicago Produits de fusion anticorps-LIGHT pour les thérapies du cancer
JP2010539243A (ja) 2007-09-18 2010-12-16 ラ ホヤ インスティテュート フォア アラージー アンド イムノロジー 喘息、肺及び気道の炎症、呼吸器、間質性、肺性および線維性疾患の処置のためのｌｉｇｈｔ阻害剤
JP2012521216A (ja) 2009-03-24 2012-09-13 テバ バイオファーマスーティカルズ ユーエスエー，インコーポレーテッド Ｌｉｇｈｔに対するヒト化抗体およびその使用
US20150056182A1 (en) 2011-11-30 2015-02-26 Chugai Seiyaku Kabushiki Kaisha Drug containing carrier into cell for forming immune complex
US20130315913A1 (en) * 2012-03-26 2013-11-28 Sanofi Anti-light antibody therapy for inflammatory bowel disease
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
PL2872646T3 (pl) 2012-07-12 2018-03-30 Institut National De La Santé Et De La Recherche Médicale (Inserm) Sposoby przewidywania czasu przeżycia i responsywności na leczenie pacjenta cierpiącego na nowotwór lity z sygnaturą przynajmniej 7 genów
CN106170498A (zh) 2014-01-14 2016-11-30 科马布有限公司 抗‑light抗体
US20150307620A1 (en) 2014-04-16 2015-10-29 University Of Connecticut Linked immunotherapeutic agonists that costimulate multiple pathways
AU2016313506A1 (en) 2015-08-21 2018-03-08 The Children's Hospital Of Philadelphia Methods of treating autoimmune conditions in patients with genetic variations in DcR3 or in a DcR3 network gene

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008027338A2 (fr) * 2006-08-28 2008-03-06 Kyowa Hakko Kirin Co., Limited Anticorps monoclonaux humains anti-hlight humain
US20190315876A1 (en) * 2018-01-24 2019-10-17 Capella Bioscience Ltd. Antigen Binding Molecules That Bind LIGHT

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CONVERTINO IRMA ET AL: "Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients", CRITICAL CARE, vol. 24, no. 1, 11 June 2020 (2020-06-11), XP055879485, Retrieved from the Internet <URL:https://ccforum.biomedcentral.com/track/pdf/10.1186/s13054-020-03020-3.pdf> [retrieved on 20231220], DOI: 10.1186/s13054-020-03020-3 *
PERLIN DAVID S ET AL: "Levels of the TNF-Related Cytokine LIGHT Increase in Hospitalized COVID-19 Patients with Cytokine Release Syndrome and ARDS", MSPHERE, vol. 5, no. 4, 12 August 2020 (2020-08-12), pages e00699 - 20, XP093114352, DOI: 10.1128/mSphere.00699-20 *
PERLIN DAVID S. ET AL: "Randomized, double-blind, controlled trial of human anti-LIGHT monoclonal antibody in COVID-19 acute respiratory distress syndrome", THE JOURNAL OF CLINICAL INVESTIGATION : JCI, vol. 132, no. 3, 1 February 2022 (2022-02-01), US, XP093114353, ISSN: 1558-8238, DOI: 10.1172/JCI153173 *
RAGEL EMMA J ET AL: "Acute respiratory distress syndrome: potential of therapeutic interventions effective in treating progression from COVID-19 to treat progression from other illnesses-a systematic review", BMJ OPEN RESPIRATORY RESEARCH, vol. 10, no. 1, 1 September 2023 (2023-09-01), pages e001525, XP093114358, ISSN: 2052-4439, DOI: 10.1136/bmjresp-2022-001525 *

Also Published As

Publication number Publication date
AU2021248833A1 (en) 2022-09-22
KR20220161387A (ko) 2022-12-06
EP4126945A2 (fr) 2023-02-08
CA3173873A1 (fr) 2021-10-07
US20240002492A1 (en) 2024-01-04
US20210324066A1 (en) 2021-10-21
WO2021202649A3 (fr) 2021-11-11
WO2021202649A2 (fr) 2021-10-07
US11708406B2 (en) 2023-07-25
JP2023520216A (ja) 2023-05-16
CN115768791B (zh) 2024-05-24
BR112022019112A2 (pt) 2022-11-08
CN115768791A (zh) 2023-03-07
TW202204405A (zh) 2022-02-01
MX2022011811A (es) 2022-10-07

Similar Documents

Publication Publication Date Title
AU2018317824A1 (en) Light based therapy devices and methods
EP3668594A4 (fr) Dispositifs et procédés de thérapie à base de lumière
EP4096712A4 (fr) Sars-cov-2 désoptimisé et ses procédés d&#39;utilisation
EP3873596A4 (fr) Méthode et appareil de traitement par luminothérapie
EP4113430A4 (fr) Procédé et dispositif de traitement de beauté
EP3983062A4 (fr) Systèmes et procédés de traitement esthétique
EP3785765A4 (fr) Source de lumière de traitement oculaire et dispositif de traitement oculaire la comprenant
EP3833285A4 (fr) Traitement de tissu avec un sensibilisateur et une lumière et/ou un son
EP4138933A4 (fr) Procédés et dispositifs de rayonnement lumineux anti-infectieux
EP4117655A4 (fr) Méthodes de traitement
EP4153297A4 (fr) Article de luminothérapie pouvant être porté
EP3983061A4 (fr) Systèmes et procédés de luminothérapie
EP4023278A4 (fr) Cathéter et système d&#39;exposition à la lumière
GB202205901D0 (en) Optical properties and methods for UV treatment
EP4126945A4 (fr) Méthodes et traitement impliquant un excès de light libre
EP4135836A4 (fr) Dispositif de traitement par la lumière
EP4164619A4 (fr) Méthodes de traitement et formulations
EP4082577A4 (fr) Procédé de traitement du cancer et médicament
EP4100819A4 (fr) Système et procédé de traitement de réalité virtuelle
EP4181034A4 (fr) Solution de problème d&#39;optimisation et appareil de solution de problème d&#39;optimisation
AU2020291391A1 (en) Wearable phototherapy apparatus with anti-viral and other effects
EP3923043A4 (fr) Structure optique et procédé de réduction d&#39;artéfact
EP3915500A4 (fr) Instrument de traitement d&#39;énergie et système de traitement
EP3757627A4 (fr) Corps optique empilé en résine et procédé de fabrication associé
AU2020900782A0 (en) Treatment Methods

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20221024

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: C07K0016240000

Ipc: C07K0016280000

A4 Supplementary search report drawn up and despatched

Effective date: 20240129

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/68 20060101ALI20240123BHEP

Ipc: A61P 31/14 20060101ALI20240123BHEP

Ipc: A61P 37/06 20060101ALI20240123BHEP

Ipc: A61P 29/00 20060101ALI20240123BHEP

Ipc: A61P 11/00 20060101ALI20240123BHEP

Ipc: A61P 1/00 20060101ALI20240123BHEP

Ipc: A61K 39/395 20060101ALI20240123BHEP

Ipc: C07K 16/28 20060101AFI20240123BHEP